Please Wait.....
Report
Global Drug Delivery Devices Market
Market Report I 2024-08-01 I 503 Pages I Data Bridge Market Research
The global drug delivery devices market is expected to reach USD 3,164.51 billion by 2031 from USD 1,748.63 billion in 2023, growing at a CAGR of 8.0% in the forecast period of 2024 to 2031.
Market Segmentation:
Global Drug Delivery Devices Market, By Product Type (Oral Drug Delivery, Injectable Drug Delivery, Topical Drug Delivery, Ophthalmic Drug Delivery, Nasal Drug Delivery, Pulmonary Drug Delivery, Transmucosal Drug Delivery, and Implantable Drug Delivery), End User (Hospitals, Home Healthcare, Clinics, Community Healthcare, and Others), Distribution Channel (Direct Tenders, Hospital Pharmacies, Pharmacy Stores, and Online Pharmacy), Country (U.S., Canada, Mexico, Germany, U.K., Italy, France, Spain, Russia, Switzerland, Turkey, Belgium, Netherlands, rest of Europe, Japan, China, South Korea, India, Singapore, Thailand, Indonesia, Malaysia, Philippines, Australia, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, Egypt, Saudi Arabia, U.A.E., Israel, and rest of Middle East and Africa) - Industry Trends and Forecast to 2031
Overview of Global Drug Delivery Devices Market Dynamics:
Driver
- Rising prevalence of chronic disease and non-chronic disease
Restraint
- High costs of injectable drugs
Opportunity
- Rising acceptance of self-administering drug devices
Market Players:
The key market players operating in the global drug delivery devices market are listed below:
- Johnson & Johnson Services, Inc.
- Novartis AG
- F.Hoffmann-La Roche Ltd
- Bayer AG
- Pfizer Inc.
- 3M
- AbbVie Inc.
- Amgen Inc.
- BD
- Elcam Medical
- Enable Injections
- Gerresheimer AG
- GSK plc.
- Insulet Corporation
- Medmix
- Merck & Co., Inc.
- OraSure Technologies Inc.
- Sanofi
- SMC Ltd.
- ViVO Smart Medical Devices Ltd.
- West Pharmaceutical Services Inc.
1 INTRODUCTION 67
1.1 OBJECTIVES OF THE STUDY 67
1.2 MARKET DEFINITION 67
1.3 OVERVIEW OF THE GLOBAL DRUG DELIVERY DEVICES MARKET 67
1.4 CURRENCY AND PRICING 69
1.5 LIMITATIONS 69
1.6 MARKETS COVERED 69
2 MARKET SEGMENTATION 73
2.1 MARKETS COVERED 73
2.2 GEOGRAPHICAL SCOPE 74
2.3 YEARS CONSIDERED FOR THE STUDY 75
2.4 DBMR TRIPOD DATA VALIDATION MODEL 76
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 79
2.6 MULTIVARIATE MODELLING 80
2.7 MARKET END USER COVERAGE GRID 81
2.8 PRODUCT TYPE LIFELINE CURVE 81
2.9 DBMR MARKET POSITION GRID 82
2.10 VENDOR SHARE ANALYSIS 83
2.11 SECONDARY SOURCES 84
2.12 ASSUMPTIONS 84
3 EXECUTIVE SUMMARY 85
4 PREMIUM INSIGHTS 90
4.1 PORTERS FIVE FORCES 93
4.2 PESTEL ANALYSIS 94
5 REGULATORY FRAMEWORK 95
6 MARKET OVERVIEW 96
6.1 DRIVERS 98
6.1.1 RISING PREVALENCE OF CHRONIC DISEASE AND NON-CHRONIC DISEASE 98
6.1.2 GROWTH IN THE DEVELOPMENT OF BIOLOGICS DRUGS DEVICES 98
6.1.3 INCREASING AWARENESS ABOUT DIAGNOSIS AND TREATMENT 100
6.1.4 INCREASED FOCUS ON PERSONALIZED MEDICINE AND DEVICES 100
?
6.2 RESTRAINTS 101
6.2.1 RISK OF NEEDLE-STICK INJURIES AND SIDE EFFECTS 101
6.2.2 HIGH COSTS OF INJECTABLE DRUGS 102
6.2.3 STRINGENT REGULATORY SCENARIO 103
6.3 OPPORTUNITIES 104
6.3.1 RISING ACCEPTANCE OF SELF-ADMINISTERING DRUG DEVICES 104
6.3.2 RISING DEMAND FOR BIOSIMILAR AND GENERIC DRUGS 104
6.3.3 THERAPEUTIC ADVANCEMENTS IN THE FIELD OF DRUG DELIVERY 105
6.4 CHALLENGES 105
6.4.1 SIDE EFFECTS OF DRUG DELIVERY SYSTEMS 105
6.4.2 INCREASE IN THE NUMBER OF ALTERNATIVES OF DRUG DELIVERY 106
7 GLOBAL DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE 107
7.1 OVERVIEW 108
7.2 ORAL DRUG DELIVERY 111
7.2.1 SOLID ORAL DRUGS 112
7.2.1.1 TABLETS 112
7.2.1.2 CAPSULES 112
7.2.1.3 PILLS 112
7.2.1.4 POWDERS 112
7.2.2 LIQUID ORAL DRUGS 113
7.2.2.1 SYRUPS 113
7.2.2.2 SOLUTIONS 113
7.2.3 SEMI SOLID ORAL DRUGS 113
7.2.3.1 GELS 113
7.2.3.2 EMULSIONS 113
7.2.3.3 ELIXIRS 114
7.3 INJECTABLE DRUG DELIVERY 114
7.3.1 INJECTABLE DRUG DELIVERY FORMULATIONS 115
7.3.1.1 CONVENTIONAL DRUG DELIVERY FORMULATIONS 115
7.3.1.2 NOVEL DRUG DELIVERY FORMULATIONS 115
7.3.1.3 LONG ACTING INJECTION FORMULATIONS 115
7.3.2 INJECTABLE DRUG DELIVERY DEVICES 116
7.3.2.1 CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES 116
7.3.2.1.1 BY MATERIAL 116
7.3.2.1.1.1 GLASS 116
7.3.2.1.1.2 PLASTIC 117
7.3.2.1.2 BY PRODUCT TYPE 117
7.3.2.1.2.1 FILLABLE 117
7.3.2.1.2.2 PRE-FILLED 117
?
7.3.2.1.3 BY USABILITY 117
7.3.2.1.3.1 REUSABLE SYRINGES 117
7.3.2.1.3.2 DISPOSABLE SYRINGES 118
7.3.2.2 SELF INJECTION DRUG DELIVERY DEVICES 118
7.3.2.2.1 NEEDLE FREE INJECTORS 118
7.3.2.2.2 WEARABLE INJECTORS 118
7.3.2.2.3 PEN INJECTOR 118
7.3.2.2.4 AUTO INJECTORS 118
7.3.2.2.5 OTHERS 119
7.4 TOPICAL DRUG DELIVERY 120
7.4.1 TRANSDERMAL DRUG DELIVERY FORMULATIONS 120
7.4.1.1 SEMI-SOLID TOPICAL DRUG DELIVERY FORMULATIONS 121
7.4.1.1.1 OINTMENTS 121
7.4.1.1.2 CREAMS 121
7.4.1.1.3 LOTIONS 121
7.4.1.1.4 GELS 121
7.4.1.1.5 PASTES 121
7.4.1.2 LIQUID TOPICAL DRUG DELIVERY FORMULATIONS 122
7.4.1.2.1 SUSPENSIONS 122
7.4.1.2.2 SOLUTIONS 122
7.4.1.3 SOLID TOPICAL DRUG DELIVERY FORMULATIONS 122
7.4.1.3.1 POWDER 122
7.4.1.3.2 SUPPOSITORS 123
7.5 OPHTHALMIC DRUG DELIVERY 123
7.5.1 OCCULAR DRUG DELIVERY FORMULATIONS 124
7.5.1.1 LIQUID OCCULAR DRUG DELIVERY FORMULATIONS 124
7.5.1.1.1 SOLUTIONS 124
7.5.1.1.2 SUSPENSIONS 124
7.5.1.2 SEMI SOLID OCCULAR DRUG DELIVERY FORMULATIONS 125
7.5.1.2.1 GELS 125
7.5.1.2.2 OINTMENTS 125
7.5.2 OCCULAR DRUG DELIVERY DEVICES 125
7.6 NASAL DRUG DELIVERY 125
7.6.1 NASAL DROPS 126
7.6.2 NASAL SPRAYS 126
7.6.3 NASAL POWDERS 126
7.6.4 NASAL GELS 126
7.7 PULMONARY DRUG DELIVERY 126
7.7.1 METERED DOSE INHALERS (MDI) 127
7.7.2 DRY POWDER INHALERS (DPI) 127
7.7.3 NEBULIZERS 127
7.7.3.1 JET NEBULIZERS 127
7.7.3.2 ULTRASONIC NEBULIZERS 128
7.7.3.3 SOFT MIST NEBULIZERS 128
7.8 TRANSMUCOSAL DRUG DELIVERY 128
7.8.1 ORAL TRANSMUCOSAL DRUG DELIVERY 129
7.8.1.1 BUCCAL DRUG DELIVERY 129
7.8.1.2 SUBLINGUAL DRUG DELIVERY 129
7.8.2 OTHER TRANSMUCOSAL DRUG DELIVERY 129
7.8.2.1 RECTAL TRANSMUCOSAL DRUG DELIVERY 129
7.8.2.2 VAGINAL TRANSMUCOSAL DRUG DELIVERY 130
7.9 IMPLANTABLE DRUG DELIVERY 130
7.9.1 PASSIVE IMPLANTABLE DRUG DELIVERY DEVICES 130
7.9.2 ACTIVE IMPLANTABLE DRUG DELIVERY DEVICES 130
8 GLOBAL DRUG DELIVERY DEVICES MARKET, BY END USER 131
8.1 OVERVIEW 132
8.2 HOSPITALS 135
8.3 HOME HEALTHCARE 135
8.4 CLINICS 136
8.5 COMMUNITY HEALTHCARE 136
8.6 OTHERS 137
9 GLOBAL DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL 138
9.1 OVERVIEW 139
9.2 DIRECT TENDERS 142
9.3 HOSPITAL PHARMACIES 142
9.4 PHARMACY STORES 143
9.5 ONLINE PHARMACY 143
10 GLOBAL DRUG DELIVERY DEVICES MARKET, BY REGION 144
10.1 OVERVIEW 145
10.2 NORTH AMERICA 147
10.2.1 U.S. 155
10.2.2 CANADA 163
10.2.3 MEXICO 171
?
10.3 EUROPE 179
10.3.1 GERMANY 188
10.3.2 FRANCE 196
10.3.3 ITALY 204
10.3.4 U.K. 212
10.3.5 SWITZERLAND 220
10.3.6 SPAIN 228
10.3.7 NETHERLANDS 236
10.3.8 RUSSIA 244
10.3.9 TURKEY 252
10.3.10 BELGIUM 260
10.3.11 REST OF EUROPE 268
10.4 ASIA-PACIFIC 269
10.4.1 JAPAN 278
10.4.2 CHINA 286
10.4.3 INDIA 294
10.4.4 SOUTH KOREA 302
10.4.5 AUSTRALIA 310
10.4.6 THAILAND 318
10.4.7 MALAYSIA 326
10.4.8 SINGAPORE 334
10.4.9 INDONESIA 342
10.4.10 PHILIPPINES 350
10.4.11 REST OF ASIA-PACIFIC 358
10.5 SOUTH AMERICA 359
10.5.1 BRAZIL 367
10.5.2 ARGENTINA 375
10.5.3 REST OF SOUTH AMERICA 383
10.6 MIDDLE EAST AND AFRICA 384
10.6.1 SOUTH AFRICA 392
10.6.2 SAUDI ARABIA 400
10.6.3 U.A.E. 408
10.6.4 EGYPT 416
10.6.5 ISRAEL 424
10.6.6 REST OF MIDDLE EAST AND AFRICA 432
?
11 GLOBAL DRUG DELIVERY DEVICES MARKET: COMPANY LANDSCAPE 433
11.1 COMPANY SHARE ANALYSIS: GLOBAL 433
11.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 434
11.3 COMPANY SHARE ANALYSIS: EUROPE 435
11.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 436
12 SWOT ANALYSIS 437
13 COMPANY PROFILE 438
13.1 JOHNSON & JOHNSON SERVICES, INC. 438
13.1.1 COMPANY SNAPSHOT 438
13.1.2 REVENUE ANALYSIS 438
13.1.3 COMPANY SHARE ANALYSIS 439
13.1.4 PRODUCT PORTFOLIO 439
13.1.5 RECENT DEVELOPMENTS 441
13.2 NOVARTIS AG 443
13.2.1 COMPANY SNAPSHOT 443
13.2.2 REVENUE ANALYSIS 443
13.2.3 COMPANY SHARE ANALYSIS 444
13.2.4 PRODUCT PORTFOLIO 444
13.2.5 RECENT DEVELOPMENTS 444
13.3 F. HOFFMANN-LA ROCHE LTD 446
13.3.1 COMPANY SNAPSHOT 446
13.3.2 REVENUE ANALYSIS 446
13.3.3 COMPANY SHARE ANALYSIS 447
13.3.4 PRODUCT PORTFOLIO 447
13.3.5 RECENT DEVELOPMENT 447
13.4 BAYER AG 448
13.4.1 COMPANY SNAPSHOT 448
13.4.2 REVENUE ANALYSIS 448
13.4.3 COMPANY SHARE ANALYSIS 449
13.4.4 PRODUCT PORTFOLIO 449
13.5 PFIZER INC. 450
13.5.1 COMPANY SNAPSHOT 450
13.5.2 REVENUE ANALYSIS 450
13.5.3 COMPANY SHARE ANALYSIS 451
13.5.4 PRODUCT PORTFOLIO 451
13.5.5 RECENT DEVELOPMENT 451
?
13.6 3M 452
13.6.1 COMPANY SNAPSHOT 452
13.6.2 REVENUE ANALYSIS 452
13.6.3 PRODUCT PORTFOLIO 453
13.6.4 RECENT DEVELOPMENTS 453
13.7 ABBVIE INC. 454
13.7.1 COMPANY SNAPSHOT 454
13.7.2 REVENUE ANALYSIS 455
13.7.3 PRODUCT PORTFOLIO 455
13.7.4 RECENT DEVELOPMENTS 456
13.8 AMGEN INC. 457
13.8.1 COMPANY SNAPSHOT 457
13.8.2 REVENUE ANALYSIS 457
13.8.3 PRODUCT PORTFOLIO 458
13.8.4 RECENT DEVELOPMENTS 459
13.9 BD 460
13.9.1 COMPANY SNAPSHOT 460
13.9.2 REVENUE ANALYSIS 460
13.9.3 PRODUCT PORTFOLIO 461
13.9.4 RECENT DEVELOPMENT 464
13.10 ELCAM MEDICAL 465
13.10.1 COMPANY SNAPSHOT 465
13.10.2 PRODUCT PORTFOLIO 465
13.10.3 RECENT DEVELOPMENT 466
13.11 ENABLE INJECTIONS 467
13.11.1 COMPANY SNAPSHOT 467
13.11.2 PRODUCT PORTFOLIO 467
13.11.3 RECENT DEVELOPMENTS 468
13.12 GERRESHEIMER AG 470
13.12.1 COMPANY SNAPSHOT 470
13.12.2 REVENUE ANALYSIS 470
13.12.3 PRODUCT PORTFOLIO 471
13.12.4 RECENT DEVELOPMENTS 474
13.13 GSK PLC. 476
13.13.1 COMPANY SNAPSHOT 476
13.13.2 REVENUE ANALYSIS 476
13.13.3 PRODUCT PORTFOLIO 477
13.13.4 RECENT DEVELOPMENTS 479
?
13.14 INSULET CORPORATION 481
13.14.1 COMPANY SNAPSHOT 481
13.14.2 REVENUE ANALYSIS 481
13.14.3 PRODUCT PORTFOLIO 482
13.14.4 RECENT DEVELOPMENTS 482
13.15 MEDMIX 483
13.15.1 COMPANY SNAPSHOT 483
13.15.2 REVENUE ANALYSIS 483
13.15.3 PRODUCT PORTFOLIO 484
13.15.4 RECENT DEVELOPMENTS 485
13.16 MERCK & CO., INC. 487
13.16.1 COMPANY SNAPSHOT 487
13.16.2 REVENUE ANALYSIS 487
13.16.3 PRODUCT PORTFOLIO 488
13.16.4 RECENT DEVELOPMENT 488
13.17 ORASURE TECHNOLOGIES INC. 489
13.17.1 COMPANY SNAPSHOT 489
13.17.2 REVENUE ANALYSIS 489
13.17.3 PRODUCT PORTFOLIO 490
13.17.4 RECENT DEVELOPMENT 490
13.18 SANOFI 491
13.18.1 COMPANY SNAPSHOT 491
13.18.2 REVENUE ANALYSIS 491
13.18.3 PRODUCT PORTFOLIO 492
13.18.4 RECENT DEVELOPMENTS 494
13.19 SMC LTD. 495
13.19.1 COMPANY SNAPSHOT 495
13.19.2 REVENUE ANALYSIS 495
13.19.3 PRODUCT PORTFOLIO 496
13.19.4 RECENT DEVELOPMENTS 496
13.20 VIVO SMART MEDICAL DEVICES LTD. 497
13.20.1 COMPANY SNAPSHOT 497
13.20.2 PRODUCT PORTFOLIO 497
13.20.3 RECENT DEVELOPMENT 497
13.21 WEST PHARMACEUTICAL SERVICES, INC. 498
13.21.1 COMPANY SNAPSHOT 498
13.21.2 REVENUE ANALYSIS 498
13.21.3 PRODUCT PORTFOLIO 499
13.21.4 RECENT DEVELOPMENT 499
?
14 QUESTIONNAIRE 500
15 RELATED REPORTS 503
?
13.13.2 REVENUE ANALYSIS 476
13.13.3 PRODUCT PORTFOLIO 477
13.13.4 RECENT DEVELOPMENTS 479
?
13.14 INSULET CORPORATION 481
13.14.1 COMPANY SNAPSHOT 481
13.14.2 REVENUE ANALYSIS 481
13.14.3 PRODUCT PORTFOLIO 482
13.14.4 RECENT DEVELOPMENTS 482
13.15 MEDMIX 483
13.15.1 COMPANY SNAPSHOT 483
13.15.2 REVENUE ANALYSIS 483
13.15.3 PRODUCT PORTFOLIO 484
13.15.4 RECENT DEVELOPMENTS 485
13.16 MERCK & CO., INC. 487
13.16.1 COMPANY SNAPSHOT 487
13.16.2 REVENUE ANALYSIS 487
13.16.3 PRODUCT PORTFOLIO 488
13.16.4 RECENT DEVELOPMENT 488
13.17 ORASURE TECHNOLOGIES INC. 489
13.17.1 COMPANY SNAPSHOT 489
13.17.2 REVENUE ANALYSIS 489
13.17.3 PRODUCT PORTFOLIO 490
13.17.4 RECENT DEVELOPMENT 490
13.18 SANOFI 491
13.18.1 COMPANY SNAPSHOT 491
13.18.2 REVENUE ANALYSIS 491
13.18.3 PRODUCT PORTFOLIO 492
13.18.4 RECENT DEVELOPMENTS 494
13.19 SMC LTD. 495
13.19.1 COMPANY SNAPSHOT 495
13.19.2 REVENUE ANALYSIS 495
13.19.3 PRODUCT PORTFOLIO 496
13.19.4 RECENT DEVELOPMENTS 496
13.20 VIVO SMART MEDICAL DEVICES LTD. 497
13.20.1 COMPANY SNAPSHOT 497
13.20.2 PRODUCT PORTFOLIO 497
13.20.3 RECENT DEVELOPMENT 497
13.21 WEST PHARMACEUTICAL SERVICES, INC. 498
13.21.1 COMPANY SNAPSHOT 498
13.21.2 REVENUE ANALYSIS 498
13.21.3 PRODUCT PORTFOLIO 499
13.21.4 RECENT DEVELOPMENT 499
?
14 QUESTIONNAIRE 500
15 RELATED REPORTS 503
?
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security